AMG 110

Drug Profile

AMG 110

Alternative Names: AMG-110; Anti-CD3 anti-EpCAM bispecific antibody - Amgen; MT110; MT110 monoclonal antibody; Solitumomab

Latest Information Update: 24 Apr 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Micromet Inc
  • Developer Amgen
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action CD3 antigen inhibitors; Epithelial cell adhesion molecule inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 01 Jan 2015 Amgen completes a phase I trial of AMG 110 in Solid tumours in Germany (NCT00635596)
  • 07 Mar 2012 Micromet Inc has been acquired by Amgen
  • 08 Jun 2010 Interim efficacy & adverse events data from a phase I trial of IV MT 110 in Solid tumours (lung, gastrointestinal) presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO-2010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top